Allergy medications that don't cause ED are an important consideration for the millions of people in the UK managing conditions such as hay fever, allergic rhinitis, and urticaria. Whilst most allergy treatments are well tolerated, some — particularly older, sedating antihistamines with anticholinergic properties — may theoretically contribute to erectile dysfunction (ED). Understanding which treatments carry a lower risk can help patients and clinicians make better-informed decisions, ensuring effective allergy control without compromising sexual wellbeing. This article reviews the evidence, UK regulatory guidance, and practical strategies for managing allergies safely.

How Some Allergy Medications May Affect Sexual Function

Allergic conditions — including hay fever, allergic rhinitis, urticaria, and asthma — are extremely common in the UK, affecting millions of people. Managing these conditions often involves long-term use of medications, and whilst most allergy treatments are well tolerated, some can have effects on the body that extend beyond their intended purpose. One area that receives relatively little attention is the potential impact of allergy medications on sexual function, including erectile dysfunction (ED).

ED is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It is a multifactorial condition influenced by vascular, neurological, hormonal, and psychological factors. Importantly, ED can sometimes be an early marker of underlying cardiovascular disease or other systemic conditions, and any new or persistent ED warrants assessment in primary care — not simply a review of medications. Medications can contribute to ED through several mechanisms, including effects on the autonomic nervous system, hormonal pathways, or blood flow.

Understanding which allergy treatments carry a higher or lower risk of contributing to ED can help patients and clinicians make more informed prescribing decisions. It is important to note that allergic disease itself — particularly when poorly controlled — can affect quality of life, sleep, and mood, all of which are independently associated with sexual dysfunction. Therefore, the relationship between allergy, its treatment, and sexual health is nuanced. Attributing ED solely to a medication without considering the broader clinical picture can lead to unnecessary changes in treatment and suboptimal allergy management.

Antihistamines and the Risk of Erectile Dysfunction

Antihistamines are among the most widely used allergy medications in the UK, available both over the counter and on prescription. They work by blocking histamine H1 receptors, reducing symptoms such as sneezing, itching, and nasal congestion. However, not all antihistamines carry the same risk profile when it comes to sexual function.

First-generation (sedating) antihistamines — such as chlorphenamine (Piriton) and promethazine — cross the blood-brain barrier and have significant anticholinergic properties. Anticholinergic effects can theoretically impair parasympathetic nervous system activity, which plays a key role in achieving and maintaining an erection. This represents a biologically plausible mechanism, though direct clinical evidence specifically linking first-generation antihistamines to ED remains limited. These medications may also cause:

• Sedation and fatigue

• Reduced libido

• Difficulty with arousal

The MHRA-approved product information (Summary of Product Characteristics, available via the Electronic Medicines Compendium) for sedating antihistamines such as chlorphenamine and promethazine does acknowledge anticholinergic adverse effects, including urinary retention and dry mouth, consistent with this mechanism.

Second-generation (non-sedating) antihistamines — including cetirizine, loratadine, and fexofenadine — have a much lower propensity to cross the blood-brain barrier and minimal anticholinergic activity. As a result, they are considerably less likely to interfere with erectile function. ED is not listed as an adverse effect in the Summary of Product Characteristics for cetirizine, loratadine, or fexofenadine (Electronic Medicines Compendium). For most patients requiring regular antihistamine therapy, second-generation options are preferred both for their tolerability and their reduced risk of systemic side effects.

It is worth noting that whilst second-generation antihistamines are often described as 'non-drowsy', some individuals — particularly with cetirizine — may still experience drowsiness. The BNF classifies these agents as 'less sedating' rather than entirely non-sedating, and patients should be aware of this possibility.

Allergy Treatments Less Likely to Cause Erectile Dysfunction

For patients concerned about the impact of allergy treatment on sexual health, several therapeutic options are associated with a low risk of contributing to ED. Understanding these alternatives can support shared decision-making between patients and their healthcare providers.

Intranasal corticosteroids (such as fluticasone, mometasone, and beclometasone nasal sprays) are recommended as first-line treatment for moderate-to-severe or persistent allergic rhinitis according to NICE Clinical Knowledge Summary (CKS) guidance on allergic rhinitis. Because they act locally within the nasal passages with minimal systemic absorption, they are not associated with ED. They are highly effective at reducing nasal inflammation and are suitable for long-term use. For mild or intermittent symptoms, NICE CKS recommends a stepwise approach in which a less-sedating oral antihistamine may be the initial choice, with intranasal corticosteroids added or substituted if symptoms are not adequately controlled.

Second-generation antihistamines — including loratadine, cetirizine, and fexofenadine — as discussed, carry a very low risk of sexual side effects and remain a cornerstone of allergy management.

Intranasal antihistamines (such as azelastine nasal spray) offer a locally acting alternative for allergic rhinitis with minimal systemic exposure, and are not associated with ED.

Leukotriene receptor antagonists, such as montelukast, are used in allergic rhinitis and asthma. However, their use in allergic rhinitis should be reserved for patients not adequately controlled by other treatments. The MHRA issued a Drug Safety Update in 2019 highlighting the risk of neuropsychiatric reactions with montelukast — including mood changes, depression, sleep disturbances, and suicidal ideation — and advises that patients and carers are counselled about these risks before starting treatment. Whilst there is no established direct link between montelukast and ED, mood disturbances associated with its use could indirectly affect sexual function.

Decongestants (oral or topical) have a limited role in allergic rhinitis and are not recommended for long-term use. Topical nasal decongestants (such as xylometazoline) can cause rebound congestion with prolonged use, and oral decongestants (such as pseudoephedrine) carry cardiovascular risks. Neither is a preferred option for ongoing allergy management.

Allergen immunotherapy (desensitisation), available through specialist NHS allergy services following confirmation of IgE-mediated sensitisation, addresses the underlying immune response rather than simply suppressing symptoms. This approach — delivered as subcutaneous injections or sublingual tablets — is not associated with ED and may ultimately reduce the need for ongoing pharmacological treatment. It is reserved for patients with severe or refractory disease, following specialist assessment in line with BSACI guidance.

Sodium cromoglicate eye drops and nasal sprays act as mast cell stabilisers and have a very localised action with negligible systemic absorption, making them extremely unlikely to affect sexual function.

What the Evidence Says: UK Regulatory and Clinical Guidance

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for monitoring the safety of medicines in the UK. A review of MHRA Yellow Card data and published product information (Summaries of Product Characteristics, available via the Electronic Medicines Compendium) reveals that ED is not listed as a recognised adverse effect for second-generation antihistamines such as cetirizine, loratadine, or fexofenadine. For first-generation antihistamines, anticholinergic effects are acknowledged in their product information, though ED is not always explicitly named as a listed side effect.

NICE Clinical Knowledge Summaries (CKS) on allergic rhinitis and urticaria do not specifically address ED as a treatment consideration, but they do recommend less-sedating antihistamines and intranasal corticosteroids as preferred options within a stepwise management framework — choices that carry a lower burden of systemic side effects overall. NICE CKS also emphasises the importance of patient-centred care and shared decision-making, which should encompass discussions about quality of life, including sexual wellbeing.

The European Medicines Agency (EMA) similarly does not identify ED as a class effect of modern antihistamines, as reflected in the European Public Assessment Report (EPAR) for fexofenadine (Telfast). However, it is worth noting that post-marketing surveillance and real-world evidence can sometimes reveal associations not captured in clinical trials, particularly for less commonly reported outcomes such as sexual dysfunction. Patients are encouraged to report any suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Overall, the weight of current evidence suggests that modern, less-sedating allergy treatments carry a very low risk of contributing to ED, and that concerns in this area are most relevant to older, sedating antihistamines with significant anticholinergic activity.

Speaking to Your GP About Allergy Treatment and Sexual Health

Many patients feel reluctant to raise concerns about sexual health with their GP, yet ED can have a significant impact on mental health, relationships, and overall quality of life. If you suspect that an allergy medication may be contributing to erectile difficulties, it is important to discuss this openly with your doctor rather than stopping treatment abruptly. This is particularly important for anyone taking asthma controller inhalers or other regular prescribed treatments — these should never be stopped suddenly without medical advice, as doing so can cause a rapid worsening of symptoms.

When speaking to your GP, it may be helpful to:

• Note when the ED began in relation to starting or changing allergy medication

• Keep a symptom diary recording both allergy symptoms and any changes in sexual function

• Mention all medications you are taking, including over-the-counter products, as interactions can sometimes contribute to ED

• Discuss lifestyle factors such as stress, sleep quality, alcohol use, and cardiovascular health, all of which are relevant to erectile function

Your GP can review your current allergy treatment and consider switching to an alternative with a lower risk profile if appropriate. They can also assess whether ED may have an underlying cause unrelated to allergy medication — such as cardiovascular disease, diabetes, or hypogonadism — which would require separate investigation and management. NICE CKS guidance on erectile dysfunction provides a framework for assessment and referral thresholds in primary care.

Seek prompt medical advice if:

• ED develops suddenly or is accompanied by other new symptoms

• You experience chest pain, palpitations, or breathlessness alongside ED

• ED is causing significant psychological distress

GPs can refer patients to specialist allergy services or urology and sexual health services where needed, ensuring both conditions are managed effectively.

Managing Allergies Safely Without Compromising Sexual Wellbeing

Effective allergy management and a healthy sexual life are not mutually exclusive. With the range of treatments now available, it is entirely possible to control allergic symptoms well whilst minimising the risk of medication-related sexual side effects.

Practical strategies include:

• Choosing less-sedating antihistamines (loratadine, cetirizine, fexofenadine) over first-generation sedating options wherever possible, particularly for regular or long-term use. Note that even these agents may cause drowsiness in some individuals

• Using intranasal corticosteroid sprays as the primary treatment for moderate-to-severe or persistent allergic rhinitis, in line with NICE CKS guidance, as these have negligible systemic absorption

• Avoiding unnecessary use of sedating antihistamines, reserving them only for short-term use when specifically indicated (for example, acute urticaria at night)

• Avoiding long-term use of decongestants — topical nasal decongestants should be limited to short courses (typically no more than seven days) to prevent rebound congestion, and oral decongestants are not recommended for ongoing allergy management

• Considering allergen immunotherapy through an NHS specialist allergy clinic if symptoms are severe or poorly controlled and IgE-mediated sensitisation has been confirmed; this can reduce long-term medication burden but requires specialist assessment

• Addressing lifestyle factors that support both allergy control and sexual health, including regular exercise, a balanced diet, adequate sleep, and smoking cessation

It is also worth recognising that untreated or poorly managed allergies — causing chronic fatigue, disrupted sleep, and reduced quality of life — can themselves contribute to reduced libido and sexual difficulties. Achieving good allergy control is therefore an important component of overall wellbeing, including sexual health.

Open communication with your GP or pharmacist about treatment preferences and any concerns regarding side effects is key. Healthcare professionals can tailor allergy management plans to individual needs, ensuring that both symptom control and quality of life — in all its dimensions — are prioritised. Patients should never feel that they must choose between managing their allergy and maintaining their sexual health.

Frequently Asked Questions